Zacks Research Brokers Reduce Earnings Estimates for MTD

Mettler-Toledo International, Inc. (NYSE:MTD) – Investment analysts at Zacks Research dropped their Q4 2025 earnings per share estimates for shares of Mettler-Toledo International in a research report issued to clients and investors on Friday, October 24th. Zacks Research analyst Team now anticipates that the medical instruments supplier will post earnings per share of $13.10 for the quarter, down from their previous forecast of $13.23. The consensus estimate for Mettler-Toledo International’s current full-year earnings is $42.71 per share. Zacks Research also issued estimates for Mettler-Toledo International’s Q1 2027 earnings at $9.63 EPS, Q3 2027 earnings at $12.74 EPS and FY2027 earnings at $51.67 EPS.

Mettler-Toledo International (NYSE:MTD) last posted its quarterly earnings results on Thursday, July 31st. The medical instruments supplier reported $10.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $9.58 by $0.51. Mettler-Toledo International had a negative return on equity of 476.07% and a net margin of 21.46%.The business had revenue of $983.22 million for the quarter, compared to analyst estimates of $957.41 million. During the same period last year, the company earned $9.65 EPS. The firm’s revenue was up 3.9% on a year-over-year basis. Mettler-Toledo International has set its FY 2025 guidance at 42.100-42.600 EPS. Q3 2025 guidance at 10.550-10.750 EPS.

Several other research firms have also issued reports on MTD. Citigroup raised their price target on Mettler-Toledo International from $1,400.00 to $1,600.00 and gave the stock a “buy” rating in a research report on Thursday, August 21st. Barclays increased their target price on shares of Mettler-Toledo International from $1,325.00 to $1,350.00 and gave the stock an “overweight” rating in a report on Thursday, October 2nd. Evercore ISI increased their target price on shares of Mettler-Toledo International from $1,275.00 to $1,400.00 and gave the stock an “outperform” rating in a report on Tuesday, October 7th. JPMorgan Chase & Co. increased their target price on shares of Mettler-Toledo International from $1,200.00 to $1,285.00 and gave the stock a “neutral” rating in a report on Thursday, October 9th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Mettler-Toledo International in a report on Saturday. Five analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $1,336.50.

Mettler-Toledo International Stock Down 0.2%

NYSE:MTD opened at $1,435.51 on Monday. Mettler-Toledo International has a 12-month low of $946.69 and a 12-month high of $1,454.68. The firm has a market capitalization of $29.57 billion, a P/E ratio of 36.35, a P/E/G ratio of 4.31 and a beta of 1.37. The stock’s fifty day simple moving average is $1,297.24 and its 200-day simple moving average is $1,209.37.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its position in Mettler-Toledo International by 0.5% in the second quarter. Vanguard Group Inc. now owns 2,556,707 shares of the medical instruments supplier’s stock valued at $3,003,415,000 after purchasing an additional 13,342 shares in the last quarter. Bank of New York Mellon Corp grew its position in Mettler-Toledo International by 71.3% in the second quarter. Bank of New York Mellon Corp now owns 904,264 shares of the medical instruments supplier’s stock valued at $1,062,257,000 after purchasing an additional 376,419 shares in the last quarter. Alliancebernstein L.P. grew its position in Mettler-Toledo International by 1.1% in the second quarter. Alliancebernstein L.P. now owns 717,449 shares of the medical instruments supplier’s stock valued at $842,802,000 after purchasing an additional 8,121 shares in the last quarter. Geode Capital Management LLC grew its position in Mettler-Toledo International by 0.6% in the second quarter. Geode Capital Management LLC now owns 581,847 shares of the medical instruments supplier’s stock valued at $681,489,000 after purchasing an additional 3,383 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD grew its position in Mettler-Toledo International by 5.5% in the first quarter. Price T Rowe Associates Inc. MD now owns 481,011 shares of the medical instruments supplier’s stock valued at $568,032,000 after purchasing an additional 25,272 shares in the last quarter. Institutional investors own 95.07% of the company’s stock.

Insider Buying and Selling

In related news, insider Gerry Keller sold 165 shares of the firm’s stock in a transaction on Thursday, August 14th. The shares were sold at an average price of $1,308.64, for a total transaction of $215,925.60. Following the sale, the insider directly owned 94 shares in the company, valued at $123,012.16. This trade represents a 63.71% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Shawn Vadala sold 300 shares of the firm’s stock in a transaction on Tuesday, August 19th. The shares were sold at an average price of $1,325.00, for a total transaction of $397,500.00. Following the completion of the transaction, the chief financial officer directly owned 5,095 shares of the company’s stock, valued at approximately $6,750,875. This trade represents a 5.56% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 1,827 shares of company stock worth $2,371,208 over the last ninety days. Company insiders own 0.77% of the company’s stock.

Mettler-Toledo International Company Profile

Mettler-Toledo International Inc manufactures and supplies precision instruments and services in the Americas, Europe, Asia, and internationally. It operates through five segments: U.S. Operations, Swiss Operations, Western European Operations, Chinese Operations, and Other. The company’s laboratory instruments include laboratory balances, liquid pipetting solutions, automated laboratory reactors, real-time analytics, titrators, pH meters, process analytics sensors and analyzer technologies, physical value analyzers, density and refractometry, thermal analysis systems, and other analytical instruments; and LabX, a laboratory software platform to manage and analyze data generated from its instruments.